TITLE

STAT CONSULT

AUTHOR(S)
Weinstein Kaplan, Bette
PUB. DATE
May 2013
SOURCE
Oncology Nurse Advisor;May/Jun2013, Vol. 4 Issue 3, p32
SOURCE TYPE
Periodical
DOC. TYPE
Product Review
ABSTRACT
The article discusses the pharmacology of Vismodegib (Erivedge), a hedgehog signaling pathway inhibitor, from Genentech.
ACCESSION #
88088806

 

Related Articles

  • A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. Infante, Jeffrey; Jones, Suzanne; Bendell, Johanna; Greco, F.; Yardley, Denise; Lane, Cassie; Spigel, David; Hainsworth, John; Burris III, Howard // Cancer Chemotherapy & Pharmacology;Jan2012, Vol. 69 Issue 1, p137 

    Purpose: To address tolerability and a possible pharmacologic interaction of capecitabine with sorafenib. Methods: Patients with advanced solid tumors (ECOG PS 0-1) were included. Cohort A received capecitabine 750 mg/m BID and Cohort B received capecitabine 1,000 mg/m BID, both for 14 days of a...

  • Rivaroxaban: a novel anticoagulant. Haalstrup, Margaret; Williams, Helen // British Journal of Cardiac Nursing;Feb2014, Vol. 9 Issue 2, p68 

    Rivaroxaban is an oral anticoagulant licensed for the treatment of acute deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. It is also licensed for the prevention of stroke and systemic embolism in adult patients with...

  • Axitinib for Advanced Renal Cell Carcinoma.  // Clinical Oncology Alert;Mar2012, Vol. 28 Issue 3, p17 

    The author discusses a study by B. I. Rini, which showed that axitinib was superior to sorafenib in terms of progression free survival (PFS) and objective response rate and had lower rates of dermatologic adverse events. He comments that metastatic renal cell cancer remains unaffected after...

  • Perampanel approved for epilepsy. Traynor, Kate // American Journal of Health-System Pharmacy;12/ 1/2012, Vol. 69 Issue 23, p2024 

    The article reports the announcement made by Eisai Company Ltd., on FDA's approval to the drug Perampanel oral tablets, as a supplemental therapy for partial seizures for epilepsy patients. It also discusses the labeling information, the recommended dosage and the adverse reactions associated...

  • The Importance of Stroke Prevention in the Management of Atrial Fibrillation. Boyle, Noel G. // Journal of Managed Care Medicine;2013, Vol. 16 Issue 1, p7 

    The article discusses Thromboprophylaxis, an important aspect of atrial fibrillation (AF ) management to prevent stroke. All patients with AF should be assessed for stroke and bleeding risk to select the most appropriate therapy. Although warfarin continues to be the anticoagulant of choice for...

  • Rivaroxaban: a novel anticoagulant for the treatment of DVT. Haastrup, Margaret; Willimas, Helen // Nurse Prescribing;Jun2013, Vol. 11 Issue 6, p298 

    Rivaroxaban is an oral anticoagulant licensed for the treatment of acute deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. It is also licensed for the prevention of stroke and systemic embolism in adult patients with...

  • News in brief ...  // PharmacoEconomics & Outcomes News;11/20/2004, Issue 466, p5 

    Presents an update on health research as of November 20, 2004. Advantages of follow-on medicines according to a study by the Tufts Center for the Study of Drug Development; Concerns over analgesic selection among dental outpatients in Nepal; Results of an online survey on the attitude of U.S....

  • Genetic testing good to guide thienopyridine treatment.  // PharmacoEconomics & Outcomes News;10/13/2012, Issue 664, p9 

    The article discusses research on the cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes, referencing a study by L. Panattoni and colleagues.

  • Targeted agents for RCC: A role for adjuvant therapy? Gebhart, Fred // Urology Times;May2011, Vol. 39 Issue 5, p20 

    The article reports on the clinical trials that examine the effectiveness of pharmacologic and surgical therapies in the treatment of renal cell carcinoma (RCC). Doctor Hendrik Van Poppel discusses the introduction of targeted molecular therapies such as sunitinib, sorafenib, and pazopanib for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics